en · de · es · fr · pt
cardarine-notes.peptides6088.com › Data › Mechanism And Detection Methods — Field Notes

Mechanism And Detection Methods — Field Notes

By Editorial Desk · published 2026-02-13 · last reviewed 2026-04-06 · Data

Cardarine is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2026-04-06. Numbers and descriptions here follow the published literature rather than marketing material.

Mechanism and Detection Methods

GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.

Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.

Identity and Pharmacological Classification

PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.

Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.

Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.

Cardarine at a glance

PropertyValueNotes
AppearanceWhite to off-white powderVisual description for typical solid reference material.
SolubilityPoorly soluble in water; soluble in DMSOSolubility depends on solvent, purity, and form.
StorageCool, dry, protected from lightLong-term storage often uses low temperature and desiccant.
Common analytical methodLC-MS/MSUsed for detection and quantification in biological matrices.
Common synonymsGW-501516; GW501516; endurobolNaming varies among literature, vendors, and databases.

Background and Regulatory Status

Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.

Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.

Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.

Related pages on this site

Regulation and Detection

Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.

Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.

Mechanism and Detection

Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.

GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.

Cardarine as Investigational PPARδ Agonist

Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.

Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.

Supporting material

== Select academic publications == Esimone is one of the most published scholars in Nigeria: His publications have been cited 7,402 times according to the AD Scientific index ranking, and 7,463 times according to the Google Scholar index. Here are a select few:

Nuclear fission is a reaction in which the nucleus of an atom splits into two or more smaller nuclei. The fission process often produces neutrons and gamma rays, and releases a very large amount of energy even by the energetic standards of radioactive decay. The free energy released by the fission of one uranium-235 atom is about 100 million times the energy released by burning one carbon atom in air to produce CO2. Nuclear fission was discovered by chemists Otto Hahn and Fritz Strassmann and physicists Lise Meitner and Otto Robert Frisch. Hahn and Strassmann proved that a fission reaction had taken place on 19 December 1938, and Meitner and her nephew Frisch explained it theoretically in January 1939. Frisch named the process "fission" by analogy with biological fission of living cells. In their second publication on nuclear fission in February 1939, Hahn and Strassmann predicted the existence and liberation of additional neutrons during the fission process, opening up the possibility of a nuclear chain reaction by assembling a critical mass of fissile material. For heavy nuclides, it is an exothermic reaction which releases large amounts of energy both as electromagnetic radiation and as kinetic energy of the fragments (heating the bulk material where fission takes place). Like nuclear fusion, for fission to produce energy, the total binding energy of the resulting elements must be greater than that of the starting element. The fission barrier must also be overcome.

This is indicated by swelling (edema) of the eyes and lips; asthma; bronchial irritation; dry, sore throat; congestion; skin redness (erythema); skin blisters (vesication); wheezing; itchy, watery eyes; chest tightness; and skin irritation.

. As of 1994, limited information existed on the acute toxicity of carbonyl sulfide in humans and in animals. High concentrations (above 1000 ppm) can cause sudden collapse, convulsions, and death from respiratory paralysis. Occasional fatalities have been reported, practically without local irritation or olfactory warning. In tests with rats, 50% animals died when exposed to 1400 ppm of COS for 90 minutes, or at 3000 ppm for 9 minutes. Limited studies with laboratory animals also suggest that continued inhalation of low concentrations (around 50 ppm for up to 12 weeks) does not affect the lungs or the heart. Carbonyl sulfide is a potential alternative fumigant to methyl bromide and phosphine. In some cases, however, residues on the grain result in flavours that are unacceptable to consumers, such as in barley used for brewing.

Sources: en.wikipedia.org

Notes from published material

White adipose tissue is most abundant in mammals and its distribution greatly varies among different species. Usually white adipose tissue can be found in two different locations of the body where it is stored: subcutaneous adipose tissue and intra-abdominal adipose tissue. Subcutaneous adipose tissue is directly underneath the skin, while the intra-abdominal adipose tissue surrounds the organs inside the abdomen such as intestine and kidneys. The intra-abdominal adipose tissues covers the thoracic and abdominal cavity. The visceral adipose tissue is part of the intra-abdominal adipose tissue that surrounds the intestine for the most part. White adipose tissue exists mostly as a single adipocytes in the subcutaneous tissue.

Sickle cell disease (SCD), also simply called sickle cell, is a group of inherited hemoglobin-related blood disorders. Sickle cell disease is caused by an abnormality in the oxygen-carrying protein haemoglobin found in red blood cells. This leads to the red blood cells adopting an abnormal sickle-like shape under certain circumstances. With this shape, they cannot deform as they pass through capillaries, causing blockages. Problems in sickle cell disease typically begin around 5 to 6 months of age. Several health problems may develop, such as attacks of pain (known as a sickle cell crisis) in joints, anaemia, swelling in the hands and feet, bacterial infections, dizziness and stroke. The probability of severe symptoms, including long-term pain, increases with age. Without treatment, people with sickle cell disease rarely reach adulthood, but with good healthcare, median life expectancy is between 58 and 66 years. All of the major organs are affected by sickle cell disease. The liver, heart, kidneys, lungs, gallbladder, eyes, bones, and joints can be damaged by abnormal sickle cells and their inability to flow through the small blood vessels. Sickle cell disease occurs when a person inherits two abnormal copies of the β-globin gene that make haemoglobin, one from each parent. The abnormal gene generates haemoglobin S (HbS) which changes the properties of red blood cells.

Mandelbaum (1956), professor at the University of Pennsylvania School of Design Kenneth Silverman (1956), professor at New York University and Pulitzer Prize-winning biographer Robert Alter (1957), professor of Hebrew and comparative literature at the University of California, Berkeley; president of the Association of Literary Scholars, Critics, and Writers Stanley Corngold (1957), professor of literature at Princeton University George Dargo (1957), legal scholar, professor at New England Law Boston Erich S. Gruen (1957), classicist and ancient historian; president of the Society for Classical Studies in 1992 Stanley Insler (1957), philologist and professor at Yale University Jonathan Lubin (1957), professor of mathematics at Brown University; introduced Lubin–Tate formal group law Robert Chazan (1958), professor of Judaic studies at New York University Gerald Feldman (1958), historian who specializes in 20th-century German history; professor at University of California, Berkeley Robert M. Fogelson (1958), urban historian at Massachusetts Institute of Technology Robert W.

Phlebotomies are carried out by phlebotomists – people trained to draw blood mostly from veins for clinical or medical testing, transfusions, donations, or research. Blood is collected primarily by performing venipunctures, or by using capillary blood sampling with fingersticks or a heel stick in infants for the collection of minute quantities of blood. The duties of a phlebotomist may include interpreting the tests requested, drawing blood into the correct tubes with the proper additives, accurately explaining the procedure to the person and preparing them accordingly, practicing the required forms of asepsis, practicing standard and universal precautions, restoring hemostasis of the puncture site, giving instructions on post-puncture care, affixing tubes with electronically printed labels, and delivering specimens to a laboratory. Some countries, states, or districts require that phlebotomists be licensed or registered. A therapeutic phlebotomy may be carried out in the treatment of some blood disorders (examples: hemochromatosis, polycythemia vera, porphyria cutanea tarda), and chronic hives (in research).

==== Metabolism ==== Atenolol undergoes minimal or negligible metabolism by the liver. It has been estimated that about 5% of atenolol is metabolized. This is in contrast to other beta blockers like propranolol and metoprolol, but is similar to nadolol. In accordance with its lack of hepatic metabolism, the pharmacokinetics of atenolol are not altered in hepatic impairment, unlike the case of propranolol. Two metabolites of atenolol have been identified: hydroxyatenolol and atenolol glucuronide. It has been said that it is unknown if these metabolites are active. However, another source stated that hydroxyatenolol has one-tenth the beta-blocking activity of atenolol.

Sources: en.wikipedia.org

Frequently asked questions

What receptor does cardarine target?

Cardarine targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not bind the androgen receptor in the way SARMs do.

How is cardarine detected in samples?

Most methods use liquid chromatography with tandem mass spectrometry. Urine is common in anti-doping testing, and blood or plasma may be used in research.

How should cardarine reference material be stored?

Typical guidance is cool, dry, dark storage, often at low temperature and with desiccant. Stability data are limited, so storage conditions should be verified for each batch or supplier.

What is cardarine also known as?

Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.

Network